Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Descovy noninferior to Truvada for PrEP

Key clinical point: Descovy for PrEP is going to be a tough sell when generic Truvada hits the market.

Major finding: PrEP failed in just two men at high risk for HIV, one in the Descovy arm and one in the Truvada arm. The drugs were equally safe.

Study details: Randomized trial involving more than 5,000 men.

Disclosures: The work was funded by Gilead; four investigators, including the senior investigator, were employees. The presenter was an investigator for the company.

Citation:

Hare CB et al. CROI 2019, Abstract 104 LB.